View ValuationWON TECHLtd 향후 성장Future 기준 점검 3/6WON TECHLtd (는) 각각 연간 17.3% 및 19.5% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 29.1% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 26% 로 예상됩니다.핵심 정보17.3%이익 성장률29.11%EPS 성장률Medical Equipment 이익 성장45.5%매출 성장률19.5%향후 자기자본이익률25.97%애널리스트 커버리지Low마지막 업데이트24 Apr 2026최근 향후 성장 업데이트Major Estimate Revision • Apr 17Consensus EPS estimates increase by 15%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has improved. 2026 revenue forecast increased from ₩185.6m to ₩189.4m. EPS estimate increased from ₩456 to ₩526 per share. Net income forecast to grow 34% next year vs 64% growth forecast for Medical Equipment industry in South Korea. Consensus price target broadly unchanged at ₩10,600. Share price rose 6.8% to ₩7,650 over the past week.Price Target Changed • Apr 16Price target decreased by 8.6% to ₩10,600Down from ₩11,600, the current price target is an average from 5 analysts. New target price is 40% above last closing price of ₩7,580. Stock is down 11% over the past year. The company is forecast to post earnings per share of ₩526 for next year compared to ₩393 last year.Major Estimate Revision • Apr 07Consensus EPS estimates fall by 25%The consensus outlook for fiscal year 2026 has been updated. 2026 EPS estimate fell from ₩607 to ₩456 per share. Revenue forecast steady at ₩185.6m. Net income forecast to grow 16% next year vs 57% growth forecast for Medical Equipment industry in South Korea. Consensus price target down from ₩11,600 to ₩10,800. Share price was steady at ₩6,650 over the past week.Price Target Changed • Nov 20Price target decreased by 11% to ₩11,200Down from ₩12,600, the current price target is an average from 5 analysts. New target price is 49% above last closing price of ₩7,520. Stock is up 68% over the past year. The company is forecast to post earnings per share of ₩524 for next year compared to ₩327 last year.Major Estimate Revision • May 14Consensus revenue estimates increase by 18%The consensus outlook for revenues in fiscal year 2025 has improved. 2025 revenue forecast increased from ₩134.6m to ₩159.0m. EPS estimate increased from ₩407 to ₩559 per share. Net income forecast to grow 72% next year vs 36% growth forecast for Medical Equipment industry in South Korea. Consensus price target of ₩7,400 unchanged from last update. Share price rose 10% to ₩9,270 over the past week.Price Target Changed • Mar 25Price target decreased by 22% to ₩6,167Down from ₩7,938, the current price target is an average from 6 analysts. New target price is approximately in line with last closing price of ₩6,130. Stock is down 36% over the past year. The company is forecast to post earnings per share of ₩389 for next year compared to ₩327 last year.모든 업데이트 보기Recent updates공시 • May 14WON TECH Co.,Ltd. announced that it expects to receive KRW 75 billion in fundingWON TECH Co.,Ltd. announced a private placement to issue series 3 bearer-type unsecured private placement convertible bonds for gross proceeds of KRW 75,000,000,000 on May 14, 2026. The transaction includes participation from new investors, Beauty Device 2026 PEF for KRW of 40,000,000,000 and PACM KOSDAQ Venture No. 1 General Private Equity Investment Trust, a fund advised by NH Investment & Securities Co., Ltd for KRW 35,000,000,000. The bonds have zero coupon rate and zero yield to maturity rate. The bonds will mature on May 22, 2031. The bonds will be 100% converted into 9,068,923 common shares at a fixed conversion price of KRW 8,270 per share. The conversion period is from May 22, 2027 to April 22, 2031. The payment date of the transaction is May 22, 2026. The transaction has been approved by the board of directors of the company. The securities are subject to prohibition of conversion, division, and merger for one year from the bond issuance date.Valuation Update With 7 Day Price Move • May 11Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₩8,860, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 11x in the Medical Equipment industry in South Korea. Total returns to shareholders of 15% over the past three years.Major Estimate Revision • Apr 17Consensus EPS estimates increase by 15%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has improved. 2026 revenue forecast increased from ₩185.6m to ₩189.4m. EPS estimate increased from ₩456 to ₩526 per share. Net income forecast to grow 34% next year vs 64% growth forecast for Medical Equipment industry in South Korea. Consensus price target broadly unchanged at ₩10,600. Share price rose 6.8% to ₩7,650 over the past week.Price Target Changed • Apr 16Price target decreased by 8.6% to ₩10,600Down from ₩11,600, the current price target is an average from 5 analysts. New target price is 40% above last closing price of ₩7,580. Stock is down 11% over the past year. The company is forecast to post earnings per share of ₩526 for next year compared to ₩393 last year.공시 • Apr 11WON TECH Co.,Ltd. (KOSDAQ:A336570) announces an Equity Buyback for KRW 6,000 million worth of its shares.WON TECH Co.,Ltd. (KOSDAQ:A336570) announces a share repurchase program. Under the program, the company will repurchase up to for KRW 6,000 million worth of its shares pursuant to a contract with Samsung Securities. The purpose of the program is to stabilize stock price, employee compensation and enhancement of shareholder value. The program will expire on October 10, 2026. As of April 9, 2026, the company had 741,749 treasury stock within the scope of dividend and 3,793 treasury stock within the scope of other acquisition.Major Estimate Revision • Apr 07Consensus EPS estimates fall by 25%The consensus outlook for fiscal year 2026 has been updated. 2026 EPS estimate fell from ₩607 to ₩456 per share. Revenue forecast steady at ₩185.6m. Net income forecast to grow 16% next year vs 57% growth forecast for Medical Equipment industry in South Korea. Consensus price target down from ₩11,600 to ₩10,800. Share price was steady at ₩6,650 over the past week.분석 기사 • Mar 29We Think WON TECHLtd's (KOSDAQ:336570) Solid Earnings Are UnderstatedThe stock was sluggish on the back of WON TECH Co.,Ltd.'s ( KOSDAQ:336570 ) recent earnings report. Our analysis...공시 • Mar 10WON TECH Co.,Ltd., Annual General Meeting, Mar 27, 2026WON TECH Co.,Ltd., Annual General Meeting, Mar 27, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 64, techno 8-ro, yuseong-gu, daejeon South KoreaValuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩6,600, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 13% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩11,278 per share.Buy Or Sell Opportunity • Feb 05Now 23% undervaluedOver the last 90 days, the stock has risen 9.4% to ₩8,860. The fair value is estimated to be ₩11,478, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 26%. Revenue is forecast to grow by 45% in 2 years. Earnings are forecast to grow by 52% in the next 2 years.Valuation Update With 7 Day Price Move • Jan 30Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩10,220, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 117% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩11,310 per share.분석 기사 • Jan 28Does WON TECHLtd (KOSDAQ:336570) Deserve A Spot On Your Watchlist?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Valuation Update With 7 Day Price Move • Jan 02Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩8,250, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 102% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩11,331 per share.Price Target Changed • Nov 20Price target decreased by 11% to ₩11,200Down from ₩12,600, the current price target is an average from 5 analysts. New target price is 49% above last closing price of ₩7,520. Stock is up 68% over the past year. The company is forecast to post earnings per share of ₩524 for next year compared to ₩327 last year.Reported Earnings • Nov 14Third quarter 2025 earnings released: EPS: ₩88.00 (vs ₩54.00 in 3Q 2024)Third quarter 2025 results: EPS: ₩88.00 (up from ₩54.00 in 3Q 2024). Revenue: ₩33.2b (up 24% from 3Q 2024). Net income: ₩7.89b (up 64% from 3Q 2024). Profit margin: 24% (up from 18% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Medical Equipment industry in South Korea. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth.공시 • Oct 20WON TECH Co.,Ltd. (KOSDAQ:A336570) announces an Equity Buyback for KRW 6,000 million worth of its shares.WON TECH Co.,Ltd. (KOSDAQ:A336570) announces a share repurchase program. Under the program, the company will repurchase up to for KRW 6,000 million worth of its shares. The program will expire on April 20, 2026.Buy Or Sell Opportunity • Oct 14Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 29% to ₩8,970. The fair value is estimated to be ₩11,268, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Earnings per share has grown by 26%. Revenue is forecast to grow by 39% in 2 years. Earnings are forecast to grow by 51% in the next 2 years.분석 기사 • Sep 11Investors Shouldn't Overlook The Favourable Returns On Capital At WON TECHLtd (KOSDAQ:336570)If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...분석 기사 • Aug 26WON TECH Co.,Ltd. (KOSDAQ:336570) Shares May Have Slumped 25% But Getting In Cheap Is Still UnlikelyWON TECH Co.,Ltd. ( KOSDAQ:336570 ) shares have retraced a considerable 25% in the last month, reversing a fair amount...Reported Earnings • Aug 16Second quarter 2025 earnings released: EPS: ₩103 (vs ₩50.00 in 2Q 2024)Second quarter 2025 results: EPS: ₩103 (up from ₩50.00 in 2Q 2024). Revenue: ₩39.8b (up 37% from 2Q 2024). Net income: ₩9.20b (up 108% from 2Q 2024). Profit margin: 23% (up from 15% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Medical Equipment industry in South Korea. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 51% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Aug 13Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩10,450, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 16x in the Medical Equipment industry in South Korea. Total returns to shareholders of 244% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩11,007 per share.분석 기사 • Aug 12Is WON TECHLtd (KOSDAQ:336570) Using Too Much Debt?KOSDAQ:A336570 1 Year Share Price vs Fair Value Explore WON TECHLtd's Fair Values from the Community and select yours...Buy Or Sell Opportunity • Jul 25Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 65% to ₩13,250. The fair value is estimated to be ₩10,991, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 19%. Revenue is forecast to grow by 38% in 2 years. Earnings are forecast to grow by 53% in the next 2 years.Buy Or Sell Opportunity • Jun 30Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 65% to ₩11,450. The fair value is estimated to be ₩9,329, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 19%. Revenue is forecast to grow by 33% in 2 years. Earnings are forecast to grow by 42% in the next 2 years.분석 기사 • Jun 02WON TECH Co.,Ltd.'s (KOSDAQ:336570) Intrinsic Value Is Potentially 24% Below Its Share PriceKey Insights Using the 2 Stage Free Cash Flow to Equity, WON TECHLtd fair value estimate is ₩7,805 WON TECHLtd is...Buy Or Sell Opportunity • May 29Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 39% to ₩9,360. The fair value is estimated to be ₩7,788, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 19%. Revenue is forecast to grow by 27% in 2 years. Earnings are forecast to grow by 44% in the next 2 years.Reported Earnings • May 18First quarter 2025 earnings released: EPS: ₩135 (vs ₩67.00 in 1Q 2024)First quarter 2025 results: EPS: ₩135 (up from ₩67.00 in 1Q 2024). Revenue: ₩37.4b (up 66% from 1Q 2024). Net income: ₩11.9b (up 101% from 1Q 2024). Profit margin: 32% (up from 26% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in South Korea. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth.Major Estimate Revision • May 14Consensus revenue estimates increase by 18%The consensus outlook for revenues in fiscal year 2025 has improved. 2025 revenue forecast increased from ₩134.6m to ₩159.0m. EPS estimate increased from ₩407 to ₩559 per share. Net income forecast to grow 72% next year vs 36% growth forecast for Medical Equipment industry in South Korea. Consensus price target of ₩7,400 unchanged from last update. Share price rose 10% to ₩9,270 over the past week.분석 기사 • May 09WON TECHLtd (KOSDAQ:336570) Is Reinvesting To Multiply In ValueIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. In a perfect...분석 기사 • Apr 17WON TECH Co.,Ltd.'s (KOSDAQ:336570) Shares May Have Run Too Fast Too SoonWith a price-to-earnings (or "P/E") ratio of 24.6x WON TECH Co.,Ltd. ( KOSDAQ:336570 ) may be sending very bearish...Valuation Update With 7 Day Price Move • Apr 03Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩7,250, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total returns to shareholders of 59% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩8,009 per share.Price Target Changed • Mar 25Price target decreased by 22% to ₩6,167Down from ₩7,938, the current price target is an average from 6 analysts. New target price is approximately in line with last closing price of ₩6,130. Stock is down 36% over the past year. The company is forecast to post earnings per share of ₩389 for next year compared to ₩327 last year.Upcoming Dividend • Mar 21Upcoming dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 28 March 2025. Payment date: 25 April 2025. Payout ratio is a comfortable 18% but the company is paying out more than the cash it is generating. Trailing yield: 0.8%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (1.3%).공시 • Mar 08WON TECH Co.,Ltd., Annual General Meeting, Mar 28, 2025WON TECH Co.,Ltd., Annual General Meeting, Mar 28, 2025, at 11:00 Tokyo Standard Time. Location: conference room, 64, techno 8-ro, yuseong-gu, daejeon South Korea분석 기사 • Jan 06Market Participants Recognise WON TECH Co.,Ltd.'s (KOSDAQ:336570) Earnings Pushing Shares 30% HigherThose holding WON TECH Co.,Ltd. ( KOSDAQ:336570 ) shares would be relieved that the share price has rebounded 30% in...Valuation Update With 7 Day Price Move • Jan 03Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₩5,330, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 11x in the Medical Equipment industry in South Korea. Total loss to shareholders of 43% over the past year.분석 기사 • Dec 16Investors Could Be Concerned With WON TECHLtd's (KOSDAQ:336570) Returns On CapitalIf we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Valuation Update With 7 Day Price Move • Dec 13Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩4,820, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total loss to shareholders of 48% over the past year.분석 기사 • Nov 25Why WON TECHLtd's (KOSDAQ:336570) Shaky Earnings Are Just The Beginning Of Its ProblemsInvestors were disappointed by WON TECH Co.,Ltd.'s ( KOSDAQ:336570 ) latest earnings release. We did some analysis, and...분석 기사 • Nov 22What You Can Learn From WON TECH Co.,Ltd.'s (KOSDAQ:336570) P/E After Its 26% Share Price CrashWON TECH Co.,Ltd. ( KOSDAQ:336570 ) shareholders that were waiting for something to happen have been dealt a blow with...Reported Earnings • Nov 20Third quarter 2024 earnings released: EPS: ₩54.00 (vs ₩101 in 3Q 2023)Third quarter 2024 results: EPS: ₩54.00 (down from ₩101 in 3Q 2023). Revenue: ₩26.9b (up 1.9% from 3Q 2023). Net income: ₩4.81b (down 45% from 3Q 2023). Profit margin: 18% (down from 33% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Medical Equipment industry in South Korea. Over the last 3 years on average, earnings per share has increased by 23% per year whereas the company’s share price has increased by 20% per year.Valuation Update With 7 Day Price Move • Nov 18Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩4,405, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total returns to shareholders of 66% over the past three years.Price Target Changed • Nov 16Price target decreased by 9.5% to ₩10,633Down from ₩11,756, the current price target is an average from 9 analysts. New target price is 119% above last closing price of ₩4,845. Stock is down 40% over the past year. The company is forecast to post earnings per share of ₩318 for next year compared to ₩441 last year.분석 기사 • Sep 17Is WON TECHLtd (KOSDAQ:336570) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Valuation Update With 7 Day Price Move • Sep 05Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩6,670, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total returns to shareholders of 177% over the past three years.Major Estimate Revision • Aug 19Consensus EPS estimates fall by 10%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from ₩147.5m to ₩144.8m. EPS estimate also fell from ₩460 per share to ₩413 per share. Net income forecast to grow 65% next year vs 69% growth forecast for Medical Equipment industry in South Korea. Consensus price target down from ₩12,167 to ₩11,778. Share price fell 12% to ₩5,730 over the past week.Reported Earnings • Aug 15Second quarter 2024 earnings released: EPS: ₩50.00 (vs ₩102 in 2Q 2023)Second quarter 2024 results: EPS: ₩50.00 (down from ₩102 in 2Q 2023). Revenue: ₩29.0b (down 4.9% from 2Q 2023). Net income: ₩4.42b (down 51% from 2Q 2023). Profit margin: 15% (down from 30% in 2Q 2023). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Medical Equipment industry in South Korea.Valuation Update With 7 Day Price Move • Jul 11Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩6,770, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 205% over the past three years.분석 기사 • Jun 14Here's Why We Think WON TECHLtd (KOSDAQ:336570) Is Well Worth WatchingIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Major Estimate Revision • May 16Consensus EPS estimates fall by 11%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from ₩161.2m to ₩149.8m. EPS estimate also fell from ₩576 per share to ₩514 per share. Net income forecast to grow 17% next year vs 64% growth forecast for Medical Equipment industry in South Korea. Consensus price target broadly unchanged at ₩13,429. Share price fell 23% to ₩8,600 over the past week.분석 기사 • May 13WON TECHLtd (KOSDAQ:336570) Seems To Use Debt Rather SparinglyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Buy Or Sell Opportunity • May 13Now 36% undervaluedOver the last 90 days, the stock has risen 2.3% to ₩8,380. The fair value is estimated to be ₩13,177, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 42% over the last year. Earnings per share has grown by 178%. For the next 3 years, revenue is forecast to grow by 20% per annum. Earnings are also forecast to grow by 21% per annum over the same time period.분석 기사 • Apr 15WON TECHLtd (KOSDAQ:336570) Could Become A Multi-BaggerFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Buy Or Sell Opportunity • Apr 05Now 21% undervaluedOver the last 90 days, the stock has risen 9.9% to ₩10,280. The fair value is estimated to be ₩12,994, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 42% over the last year. Earnings per share has grown by 179%. For the next 3 years, revenue is forecast to grow by 21% per annum. Earnings are also forecast to grow by 22% per annum over the same time period.New Risk • Apr 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (47% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (8.5% average weekly change).Valuation Update With 7 Day Price Move • Mar 28Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩9,720, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 365% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩13,055 per share.분석 기사 • Mar 25Impressive Earnings May Not Tell The Whole Story For WON TECHLtd (KOSDAQ:336570)WON TECH Co.,Ltd.'s ( KOSDAQ:336570 ) robust earnings report didn't manage to move the market for its stock. Our...Reported Earnings • Mar 21Full year 2023 earnings released: EPS: ₩441 (vs ₩158 in FY 2022)Full year 2023 results: EPS: ₩441 (up from ₩158 in FY 2022). Revenue: ₩115.6b (up 42% from FY 2022). Net income: ₩38.8b (up 190% from FY 2022). Profit margin: 34% (up from 16% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 24% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Medical Equipment industry in South Korea.Buy Or Sell Opportunity • Mar 07Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 22% to ₩7,960. The fair value is estimated to be ₩10,064, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 50% over the last year. Earnings per share has grown by 32%. Revenue is forecast to grow by 66% in 2 years. Earnings are forecast to grow by 72% in the next 2 years.Valuation Update With 7 Day Price Move • Feb 16Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩9,210, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 338% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩10,692 per share.Price Target Changed • Feb 15Price target decreased by 8.0% to ₩13,500Down from ₩14,667, the current price target is an average from 6 analysts. New target price is 61% above last closing price of ₩8,400. Stock is up 43% over the past year. The company is forecast to post earnings per share of ₩422 for next year compared to ₩158 last year.New Risk • Nov 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (31% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (8.7% average weekly change).Valuation Update With 7 Day Price Move • Nov 24Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₩10,000, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 393% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩16,716 per share.Price Target Changed • Nov 17Price target decreased by 7.2% to ₩15,083Down from ₩16,250, the current price target is an average from 6 analysts. New target price is 86% above last closing price of ₩8,130. Stock is up 135% over the past year. The company is forecast to post earnings per share of ₩441 for next year compared to ₩158 last year.Valuation Update With 7 Day Price Move • Oct 19Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩8,750, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 331% over the past three years.Valuation Update With 7 Day Price Move • Sep 21Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩10,920, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 14x in the Medical Equipment industry in South Korea. Total returns to shareholders of 442% over the past three years.New Risk • Aug 20New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 24% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. This is currently the only risk that has been identified for the company.Price Target Changed • Aug 17Price target increased by 19% to ₩15,500Up from ₩13,000, the current price target is an average from 4 analysts. New target price is 15% above last closing price of ₩13,460. Stock is up 338% over the past year. The company is forecast to post earnings per share of ₩489 for next year compared to ₩158 last year.Valuation Update With 7 Day Price Move • Aug 08Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩12,950, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 14x in the Medical Equipment industry in South Korea. Total returns to shareholders of 548% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩24,595 per share.New Risk • Aug 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Profit margins are more than 30% lower than last year (22% net profit margin).Valuation Update With 7 Day Price Move • Jun 14Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩10,300, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 414% over the past three years.Reported Earnings • May 17First quarter 2023 earnings released: EPS: ₩134 (vs ₩45.03 in 1Q 2022)First quarter 2023 results: EPS: ₩134. Revenue: ₩28.5b (up 82% from 1Q 2022). Net income: ₩11.8b (down 4.0% from 1Q 2022). Profit margin: 41% (down from 78% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 9.4% growth forecast for the Medical Equipment industry in South Korea.Valuation Update With 7 Day Price Move • May 09Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩7,770, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 14x in the Medical Equipment industry in South Korea. Total returns to shareholders of 289% over the past three years.Valuation Update With 7 Day Price Move • Mar 30Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩6,330, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 219% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩5,116 per share.이익 및 매출 성장 예측KOSDAQ:A336570 - 애널리스트 향후 추정치 및 과거 재무 데이터 (KRW Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028286,50044,85068,00074,000212/31/2027221,34365,87552,50053,333512/31/2026190,83345,80042,00042,00033/31/2026159,66933,72528,73930,352N/A12/31/2025156,83835,22149,81651,138N/A9/30/2025147,25842,96144,21945,326N/A6/30/2025140,90239,88440,78541,810N/A3/31/2025130,10435,10629,71930,925N/A12/31/2024115,25529,11312,96314,927N/A9/30/2024108,65624,4463,1265,496N/A6/30/2024108,15328,3551,6514,833N/A3/31/2024109,64532,95312,55516,087N/A12/31/2023115,62938,83322,78225,956N/A9/30/2023109,69634,51324,78227,236N/A6/30/2023103,72434,74626,20327,767N/A3/31/202392,99720,10220,83021,889N/A12/31/202281,50913,39614,20614,781N/A9/30/202272,94420,72213,65514,473N/A6/30/202265,12914,6188,0568,804N/A3/31/202256,73821,1765,6256,210N/A12/31/202151,06317,0135,5596,091N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: A336570 의 연간 예상 수익 증가율(17.3%)이 saving rate(3.1%)보다 높습니다.수익 vs 시장: A336570 의 연간 수익(17.3%)이 KR 시장(31.2%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: A336570 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: A336570 의 수익(연간 19.5%)이 KR 시장(연간 15.5%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: A336570 의 수익(연간 19.5%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: A336570의 자본 수익률은 3년 후 26%로 높을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 13:20종가2026/05/22 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스WON TECH Co.,Ltd.는 9명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Ji-Eun KimDB Financial Investment Co. Ltd.Sion KangKorea Investment & Securities Co., Ltd.Hee Ryeong JungKyobo Securities Co., Ltd6명의 분석가 더 보기
Major Estimate Revision • Apr 17Consensus EPS estimates increase by 15%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has improved. 2026 revenue forecast increased from ₩185.6m to ₩189.4m. EPS estimate increased from ₩456 to ₩526 per share. Net income forecast to grow 34% next year vs 64% growth forecast for Medical Equipment industry in South Korea. Consensus price target broadly unchanged at ₩10,600. Share price rose 6.8% to ₩7,650 over the past week.
Price Target Changed • Apr 16Price target decreased by 8.6% to ₩10,600Down from ₩11,600, the current price target is an average from 5 analysts. New target price is 40% above last closing price of ₩7,580. Stock is down 11% over the past year. The company is forecast to post earnings per share of ₩526 for next year compared to ₩393 last year.
Major Estimate Revision • Apr 07Consensus EPS estimates fall by 25%The consensus outlook for fiscal year 2026 has been updated. 2026 EPS estimate fell from ₩607 to ₩456 per share. Revenue forecast steady at ₩185.6m. Net income forecast to grow 16% next year vs 57% growth forecast for Medical Equipment industry in South Korea. Consensus price target down from ₩11,600 to ₩10,800. Share price was steady at ₩6,650 over the past week.
Price Target Changed • Nov 20Price target decreased by 11% to ₩11,200Down from ₩12,600, the current price target is an average from 5 analysts. New target price is 49% above last closing price of ₩7,520. Stock is up 68% over the past year. The company is forecast to post earnings per share of ₩524 for next year compared to ₩327 last year.
Major Estimate Revision • May 14Consensus revenue estimates increase by 18%The consensus outlook for revenues in fiscal year 2025 has improved. 2025 revenue forecast increased from ₩134.6m to ₩159.0m. EPS estimate increased from ₩407 to ₩559 per share. Net income forecast to grow 72% next year vs 36% growth forecast for Medical Equipment industry in South Korea. Consensus price target of ₩7,400 unchanged from last update. Share price rose 10% to ₩9,270 over the past week.
Price Target Changed • Mar 25Price target decreased by 22% to ₩6,167Down from ₩7,938, the current price target is an average from 6 analysts. New target price is approximately in line with last closing price of ₩6,130. Stock is down 36% over the past year. The company is forecast to post earnings per share of ₩389 for next year compared to ₩327 last year.
공시 • May 14WON TECH Co.,Ltd. announced that it expects to receive KRW 75 billion in fundingWON TECH Co.,Ltd. announced a private placement to issue series 3 bearer-type unsecured private placement convertible bonds for gross proceeds of KRW 75,000,000,000 on May 14, 2026. The transaction includes participation from new investors, Beauty Device 2026 PEF for KRW of 40,000,000,000 and PACM KOSDAQ Venture No. 1 General Private Equity Investment Trust, a fund advised by NH Investment & Securities Co., Ltd for KRW 35,000,000,000. The bonds have zero coupon rate and zero yield to maturity rate. The bonds will mature on May 22, 2031. The bonds will be 100% converted into 9,068,923 common shares at a fixed conversion price of KRW 8,270 per share. The conversion period is from May 22, 2027 to April 22, 2031. The payment date of the transaction is May 22, 2026. The transaction has been approved by the board of directors of the company. The securities are subject to prohibition of conversion, division, and merger for one year from the bond issuance date.
Valuation Update With 7 Day Price Move • May 11Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₩8,860, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 11x in the Medical Equipment industry in South Korea. Total returns to shareholders of 15% over the past three years.
Major Estimate Revision • Apr 17Consensus EPS estimates increase by 15%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has improved. 2026 revenue forecast increased from ₩185.6m to ₩189.4m. EPS estimate increased from ₩456 to ₩526 per share. Net income forecast to grow 34% next year vs 64% growth forecast for Medical Equipment industry in South Korea. Consensus price target broadly unchanged at ₩10,600. Share price rose 6.8% to ₩7,650 over the past week.
Price Target Changed • Apr 16Price target decreased by 8.6% to ₩10,600Down from ₩11,600, the current price target is an average from 5 analysts. New target price is 40% above last closing price of ₩7,580. Stock is down 11% over the past year. The company is forecast to post earnings per share of ₩526 for next year compared to ₩393 last year.
공시 • Apr 11WON TECH Co.,Ltd. (KOSDAQ:A336570) announces an Equity Buyback for KRW 6,000 million worth of its shares.WON TECH Co.,Ltd. (KOSDAQ:A336570) announces a share repurchase program. Under the program, the company will repurchase up to for KRW 6,000 million worth of its shares pursuant to a contract with Samsung Securities. The purpose of the program is to stabilize stock price, employee compensation and enhancement of shareholder value. The program will expire on October 10, 2026. As of April 9, 2026, the company had 741,749 treasury stock within the scope of dividend and 3,793 treasury stock within the scope of other acquisition.
Major Estimate Revision • Apr 07Consensus EPS estimates fall by 25%The consensus outlook for fiscal year 2026 has been updated. 2026 EPS estimate fell from ₩607 to ₩456 per share. Revenue forecast steady at ₩185.6m. Net income forecast to grow 16% next year vs 57% growth forecast for Medical Equipment industry in South Korea. Consensus price target down from ₩11,600 to ₩10,800. Share price was steady at ₩6,650 over the past week.
분석 기사 • Mar 29We Think WON TECHLtd's (KOSDAQ:336570) Solid Earnings Are UnderstatedThe stock was sluggish on the back of WON TECH Co.,Ltd.'s ( KOSDAQ:336570 ) recent earnings report. Our analysis...
공시 • Mar 10WON TECH Co.,Ltd., Annual General Meeting, Mar 27, 2026WON TECH Co.,Ltd., Annual General Meeting, Mar 27, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 64, techno 8-ro, yuseong-gu, daejeon South Korea
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩6,600, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 13% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩11,278 per share.
Buy Or Sell Opportunity • Feb 05Now 23% undervaluedOver the last 90 days, the stock has risen 9.4% to ₩8,860. The fair value is estimated to be ₩11,478, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 26%. Revenue is forecast to grow by 45% in 2 years. Earnings are forecast to grow by 52% in the next 2 years.
Valuation Update With 7 Day Price Move • Jan 30Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩10,220, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 117% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩11,310 per share.
분석 기사 • Jan 28Does WON TECHLtd (KOSDAQ:336570) Deserve A Spot On Your Watchlist?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Valuation Update With 7 Day Price Move • Jan 02Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩8,250, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 102% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩11,331 per share.
Price Target Changed • Nov 20Price target decreased by 11% to ₩11,200Down from ₩12,600, the current price target is an average from 5 analysts. New target price is 49% above last closing price of ₩7,520. Stock is up 68% over the past year. The company is forecast to post earnings per share of ₩524 for next year compared to ₩327 last year.
Reported Earnings • Nov 14Third quarter 2025 earnings released: EPS: ₩88.00 (vs ₩54.00 in 3Q 2024)Third quarter 2025 results: EPS: ₩88.00 (up from ₩54.00 in 3Q 2024). Revenue: ₩33.2b (up 24% from 3Q 2024). Net income: ₩7.89b (up 64% from 3Q 2024). Profit margin: 24% (up from 18% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Medical Equipment industry in South Korea. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Oct 20WON TECH Co.,Ltd. (KOSDAQ:A336570) announces an Equity Buyback for KRW 6,000 million worth of its shares.WON TECH Co.,Ltd. (KOSDAQ:A336570) announces a share repurchase program. Under the program, the company will repurchase up to for KRW 6,000 million worth of its shares. The program will expire on April 20, 2026.
Buy Or Sell Opportunity • Oct 14Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 29% to ₩8,970. The fair value is estimated to be ₩11,268, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Earnings per share has grown by 26%. Revenue is forecast to grow by 39% in 2 years. Earnings are forecast to grow by 51% in the next 2 years.
분석 기사 • Sep 11Investors Shouldn't Overlook The Favourable Returns On Capital At WON TECHLtd (KOSDAQ:336570)If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
분석 기사 • Aug 26WON TECH Co.,Ltd. (KOSDAQ:336570) Shares May Have Slumped 25% But Getting In Cheap Is Still UnlikelyWON TECH Co.,Ltd. ( KOSDAQ:336570 ) shares have retraced a considerable 25% in the last month, reversing a fair amount...
Reported Earnings • Aug 16Second quarter 2025 earnings released: EPS: ₩103 (vs ₩50.00 in 2Q 2024)Second quarter 2025 results: EPS: ₩103 (up from ₩50.00 in 2Q 2024). Revenue: ₩39.8b (up 37% from 2Q 2024). Net income: ₩9.20b (up 108% from 2Q 2024). Profit margin: 23% (up from 15% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Medical Equipment industry in South Korea. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 51% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Aug 13Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩10,450, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 16x in the Medical Equipment industry in South Korea. Total returns to shareholders of 244% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩11,007 per share.
분석 기사 • Aug 12Is WON TECHLtd (KOSDAQ:336570) Using Too Much Debt?KOSDAQ:A336570 1 Year Share Price vs Fair Value Explore WON TECHLtd's Fair Values from the Community and select yours...
Buy Or Sell Opportunity • Jul 25Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 65% to ₩13,250. The fair value is estimated to be ₩10,991, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 19%. Revenue is forecast to grow by 38% in 2 years. Earnings are forecast to grow by 53% in the next 2 years.
Buy Or Sell Opportunity • Jun 30Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 65% to ₩11,450. The fair value is estimated to be ₩9,329, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 19%. Revenue is forecast to grow by 33% in 2 years. Earnings are forecast to grow by 42% in the next 2 years.
분석 기사 • Jun 02WON TECH Co.,Ltd.'s (KOSDAQ:336570) Intrinsic Value Is Potentially 24% Below Its Share PriceKey Insights Using the 2 Stage Free Cash Flow to Equity, WON TECHLtd fair value estimate is ₩7,805 WON TECHLtd is...
Buy Or Sell Opportunity • May 29Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 39% to ₩9,360. The fair value is estimated to be ₩7,788, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 19%. Revenue is forecast to grow by 27% in 2 years. Earnings are forecast to grow by 44% in the next 2 years.
Reported Earnings • May 18First quarter 2025 earnings released: EPS: ₩135 (vs ₩67.00 in 1Q 2024)First quarter 2025 results: EPS: ₩135 (up from ₩67.00 in 1Q 2024). Revenue: ₩37.4b (up 66% from 1Q 2024). Net income: ₩11.9b (up 101% from 1Q 2024). Profit margin: 32% (up from 26% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in South Korea. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth.
Major Estimate Revision • May 14Consensus revenue estimates increase by 18%The consensus outlook for revenues in fiscal year 2025 has improved. 2025 revenue forecast increased from ₩134.6m to ₩159.0m. EPS estimate increased from ₩407 to ₩559 per share. Net income forecast to grow 72% next year vs 36% growth forecast for Medical Equipment industry in South Korea. Consensus price target of ₩7,400 unchanged from last update. Share price rose 10% to ₩9,270 over the past week.
분석 기사 • May 09WON TECHLtd (KOSDAQ:336570) Is Reinvesting To Multiply In ValueIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. In a perfect...
분석 기사 • Apr 17WON TECH Co.,Ltd.'s (KOSDAQ:336570) Shares May Have Run Too Fast Too SoonWith a price-to-earnings (or "P/E") ratio of 24.6x WON TECH Co.,Ltd. ( KOSDAQ:336570 ) may be sending very bearish...
Valuation Update With 7 Day Price Move • Apr 03Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩7,250, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total returns to shareholders of 59% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩8,009 per share.
Price Target Changed • Mar 25Price target decreased by 22% to ₩6,167Down from ₩7,938, the current price target is an average from 6 analysts. New target price is approximately in line with last closing price of ₩6,130. Stock is down 36% over the past year. The company is forecast to post earnings per share of ₩389 for next year compared to ₩327 last year.
Upcoming Dividend • Mar 21Upcoming dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 28 March 2025. Payment date: 25 April 2025. Payout ratio is a comfortable 18% but the company is paying out more than the cash it is generating. Trailing yield: 0.8%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (1.3%).
공시 • Mar 08WON TECH Co.,Ltd., Annual General Meeting, Mar 28, 2025WON TECH Co.,Ltd., Annual General Meeting, Mar 28, 2025, at 11:00 Tokyo Standard Time. Location: conference room, 64, techno 8-ro, yuseong-gu, daejeon South Korea
분석 기사 • Jan 06Market Participants Recognise WON TECH Co.,Ltd.'s (KOSDAQ:336570) Earnings Pushing Shares 30% HigherThose holding WON TECH Co.,Ltd. ( KOSDAQ:336570 ) shares would be relieved that the share price has rebounded 30% in...
Valuation Update With 7 Day Price Move • Jan 03Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₩5,330, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 11x in the Medical Equipment industry in South Korea. Total loss to shareholders of 43% over the past year.
분석 기사 • Dec 16Investors Could Be Concerned With WON TECHLtd's (KOSDAQ:336570) Returns On CapitalIf we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Valuation Update With 7 Day Price Move • Dec 13Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩4,820, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total loss to shareholders of 48% over the past year.
분석 기사 • Nov 25Why WON TECHLtd's (KOSDAQ:336570) Shaky Earnings Are Just The Beginning Of Its ProblemsInvestors were disappointed by WON TECH Co.,Ltd.'s ( KOSDAQ:336570 ) latest earnings release. We did some analysis, and...
분석 기사 • Nov 22What You Can Learn From WON TECH Co.,Ltd.'s (KOSDAQ:336570) P/E After Its 26% Share Price CrashWON TECH Co.,Ltd. ( KOSDAQ:336570 ) shareholders that were waiting for something to happen have been dealt a blow with...
Reported Earnings • Nov 20Third quarter 2024 earnings released: EPS: ₩54.00 (vs ₩101 in 3Q 2023)Third quarter 2024 results: EPS: ₩54.00 (down from ₩101 in 3Q 2023). Revenue: ₩26.9b (up 1.9% from 3Q 2023). Net income: ₩4.81b (down 45% from 3Q 2023). Profit margin: 18% (down from 33% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Medical Equipment industry in South Korea. Over the last 3 years on average, earnings per share has increased by 23% per year whereas the company’s share price has increased by 20% per year.
Valuation Update With 7 Day Price Move • Nov 18Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩4,405, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total returns to shareholders of 66% over the past three years.
Price Target Changed • Nov 16Price target decreased by 9.5% to ₩10,633Down from ₩11,756, the current price target is an average from 9 analysts. New target price is 119% above last closing price of ₩4,845. Stock is down 40% over the past year. The company is forecast to post earnings per share of ₩318 for next year compared to ₩441 last year.
분석 기사 • Sep 17Is WON TECHLtd (KOSDAQ:336570) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Valuation Update With 7 Day Price Move • Sep 05Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩6,670, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total returns to shareholders of 177% over the past three years.
Major Estimate Revision • Aug 19Consensus EPS estimates fall by 10%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from ₩147.5m to ₩144.8m. EPS estimate also fell from ₩460 per share to ₩413 per share. Net income forecast to grow 65% next year vs 69% growth forecast for Medical Equipment industry in South Korea. Consensus price target down from ₩12,167 to ₩11,778. Share price fell 12% to ₩5,730 over the past week.
Reported Earnings • Aug 15Second quarter 2024 earnings released: EPS: ₩50.00 (vs ₩102 in 2Q 2023)Second quarter 2024 results: EPS: ₩50.00 (down from ₩102 in 2Q 2023). Revenue: ₩29.0b (down 4.9% from 2Q 2023). Net income: ₩4.42b (down 51% from 2Q 2023). Profit margin: 15% (down from 30% in 2Q 2023). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Medical Equipment industry in South Korea.
Valuation Update With 7 Day Price Move • Jul 11Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩6,770, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 205% over the past three years.
분석 기사 • Jun 14Here's Why We Think WON TECHLtd (KOSDAQ:336570) Is Well Worth WatchingIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Major Estimate Revision • May 16Consensus EPS estimates fall by 11%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from ₩161.2m to ₩149.8m. EPS estimate also fell from ₩576 per share to ₩514 per share. Net income forecast to grow 17% next year vs 64% growth forecast for Medical Equipment industry in South Korea. Consensus price target broadly unchanged at ₩13,429. Share price fell 23% to ₩8,600 over the past week.
분석 기사 • May 13WON TECHLtd (KOSDAQ:336570) Seems To Use Debt Rather SparinglyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Buy Or Sell Opportunity • May 13Now 36% undervaluedOver the last 90 days, the stock has risen 2.3% to ₩8,380. The fair value is estimated to be ₩13,177, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 42% over the last year. Earnings per share has grown by 178%. For the next 3 years, revenue is forecast to grow by 20% per annum. Earnings are also forecast to grow by 21% per annum over the same time period.
분석 기사 • Apr 15WON TECHLtd (KOSDAQ:336570) Could Become A Multi-BaggerFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
Buy Or Sell Opportunity • Apr 05Now 21% undervaluedOver the last 90 days, the stock has risen 9.9% to ₩10,280. The fair value is estimated to be ₩12,994, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 42% over the last year. Earnings per share has grown by 179%. For the next 3 years, revenue is forecast to grow by 21% per annum. Earnings are also forecast to grow by 22% per annum over the same time period.
New Risk • Apr 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (47% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (8.5% average weekly change).
Valuation Update With 7 Day Price Move • Mar 28Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩9,720, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 365% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩13,055 per share.
분석 기사 • Mar 25Impressive Earnings May Not Tell The Whole Story For WON TECHLtd (KOSDAQ:336570)WON TECH Co.,Ltd.'s ( KOSDAQ:336570 ) robust earnings report didn't manage to move the market for its stock. Our...
Reported Earnings • Mar 21Full year 2023 earnings released: EPS: ₩441 (vs ₩158 in FY 2022)Full year 2023 results: EPS: ₩441 (up from ₩158 in FY 2022). Revenue: ₩115.6b (up 42% from FY 2022). Net income: ₩38.8b (up 190% from FY 2022). Profit margin: 34% (up from 16% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 24% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Medical Equipment industry in South Korea.
Buy Or Sell Opportunity • Mar 07Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 22% to ₩7,960. The fair value is estimated to be ₩10,064, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 50% over the last year. Earnings per share has grown by 32%. Revenue is forecast to grow by 66% in 2 years. Earnings are forecast to grow by 72% in the next 2 years.
Valuation Update With 7 Day Price Move • Feb 16Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩9,210, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 338% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩10,692 per share.
Price Target Changed • Feb 15Price target decreased by 8.0% to ₩13,500Down from ₩14,667, the current price target is an average from 6 analysts. New target price is 61% above last closing price of ₩8,400. Stock is up 43% over the past year. The company is forecast to post earnings per share of ₩422 for next year compared to ₩158 last year.
New Risk • Nov 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (31% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (8.7% average weekly change).
Valuation Update With 7 Day Price Move • Nov 24Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₩10,000, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 393% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩16,716 per share.
Price Target Changed • Nov 17Price target decreased by 7.2% to ₩15,083Down from ₩16,250, the current price target is an average from 6 analysts. New target price is 86% above last closing price of ₩8,130. Stock is up 135% over the past year. The company is forecast to post earnings per share of ₩441 for next year compared to ₩158 last year.
Valuation Update With 7 Day Price Move • Oct 19Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩8,750, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 331% over the past three years.
Valuation Update With 7 Day Price Move • Sep 21Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩10,920, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 14x in the Medical Equipment industry in South Korea. Total returns to shareholders of 442% over the past three years.
New Risk • Aug 20New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 24% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. This is currently the only risk that has been identified for the company.
Price Target Changed • Aug 17Price target increased by 19% to ₩15,500Up from ₩13,000, the current price target is an average from 4 analysts. New target price is 15% above last closing price of ₩13,460. Stock is up 338% over the past year. The company is forecast to post earnings per share of ₩489 for next year compared to ₩158 last year.
Valuation Update With 7 Day Price Move • Aug 08Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩12,950, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 14x in the Medical Equipment industry in South Korea. Total returns to shareholders of 548% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩24,595 per share.
New Risk • Aug 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Profit margins are more than 30% lower than last year (22% net profit margin).
Valuation Update With 7 Day Price Move • Jun 14Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩10,300, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 414% over the past three years.
Reported Earnings • May 17First quarter 2023 earnings released: EPS: ₩134 (vs ₩45.03 in 1Q 2022)First quarter 2023 results: EPS: ₩134. Revenue: ₩28.5b (up 82% from 1Q 2022). Net income: ₩11.8b (down 4.0% from 1Q 2022). Profit margin: 41% (down from 78% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 9.4% growth forecast for the Medical Equipment industry in South Korea.
Valuation Update With 7 Day Price Move • May 09Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩7,770, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 14x in the Medical Equipment industry in South Korea. Total returns to shareholders of 289% over the past three years.
Valuation Update With 7 Day Price Move • Mar 30Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩6,330, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 219% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩5,116 per share.